Philadelphia, United States
Cabaletta Bio (Nasdaq: CABA) is at the forefront of innovation within the biotechnology sector, focusing on engineered T cell therapies aimed at treating autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, PA, this clinical-stage company is pioneering potentially curative medical treatments, attracting considerable attention in the biopharmaceutical field.
Leveraging their proprietary CABA™ platform, the company employs two primary strategies: CARTA and CAART. Their leading candidate, CABA-201, a CD19-CAR T therapy, is under evaluation for complex conditions like systemic lupus erythematosus. This platform, promising deep and enduring responses, positions Cabaletta Bio as a promising player in the autoimmune treatment landscape.
The company's growth trajectory is underlined by their recent Post Ipo Equity investment as of 01 June 2025, marking them as a significant opportunity for investors enthusiastic about cutting-edge therapeutic innovations.
Orbital Therapeutics